Home

Corcept Therapeutics CEO

Corcept Therapeutics Expands Executive Team; Atabak Mokari

At the time of writing, our data shows that Corcept Therapeutics Incorporated has a market capitalization of US$3.1b, and reported total annual CEO compensation of US$5.0m for the year to December. Corcept is a leader in the research and development of cortisol modulators. Learn more about our work, products, and commitment to patients Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript Nov. 07, 2020 9:10 AM ET Corcept Therapeutics Incorporated (CORT) 1 Comment SA Transcript

CEO is warm, communicative and the employees like and respect him. Cons. There is a great deal of secrecy and lack of communication with employees from the president. The good people leave and under-performers are tolerated. Glassdoor has 10 Corcept Therapeutics reviews submitted anonymously by Corcept Therapeutics employees. Read employee. Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript Feb. 08, 2021 10:56 PM ET Corcept Therapeutics Incorporated (CORT) SA Transcript MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company's Board of Directors Real-time discussion about Corcept Therapeutics Incorporated (CORT) on CEO.CA, an investment chat community for Canada's small cap market Corcept Therapeutics' (CORT) CEO Joseph Belanoff On Q3 2020 Results - Quick Version Earnings Call Transcript Nov. 03, 2020 7:05 PM ET Corcept Therapeutics Incorporated (CORT) 2 Comments SA Transcript

About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. Corcept Therapeutics Appoints Gregg Alton to Board of Directors. MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the. Alton served as Gilead's interim Chief Executive Officer from January 2019 until March 2019. Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and. MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its financial results for the quarter ended March 31, 2018

Corcept Therapeutics Appoints Joshua M

  1. Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has entered into.
  2. The MarketWatch News Department was not involved in the creation of this content. MENLO PARK, Jun 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE.
  3. Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h.
  4. NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TC PipeLines, LP (NYSE:TCP), Corcept Therapeutics Incorporated (NASDAQ:CORT), Energy Recovery, Inc. (NASDAQ:ERII), Edgewell Personal Care Company (NYSE:EPC), Ocwen Financial.
  5. Corcept Therapeutics pays a modest slice of remuneration through salary, as compared to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance. NasdaqCM:CORT CEO Compensation May 20th 2021 Corcept Therapeutics Incorporated's Growt
Corcept Therapeutics: Fourth Time's A Charm For

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company's Board of Directors According to our data, Corcept Therapeutics Incorporated has a market capitalization of US$1.6b, and paid its CEO total annual compensation worth US$5.0m over the year to December 2019 Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Corcept. --Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE.

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe. Corcept Therapeutics Inc. is a pharmaceutical company that discovers and develops drugs for the treatment of severe metabolic and psychiatric disorders. The Company's lead product modulates the. Joseph Belanoff became the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) in 1999, and we think it's a good time to look at the executive's compensation against the backdrop of overall company performance.This analysis will also evaluate the appropriateness of CEO compensation when taking into account the earnings and shareholder returns of the company

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. CORCEPT THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. CORCEPT THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial.

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company's Board of Directors Joseph K. Belanoff founded Corcept Therapeutics, Inc. He is President, Chief Executive Officer & Director at this company. Dr. Belanoff is also Faculty at Stanford University. In the past Dr. Belanoff occupied the position of Psychopharmacology Director-Outpatient Division at Palo Alto Veterans Affairs Hospital. He received an undergradua Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company's Board of Directors

Corcept Therapeutics has 206 employees at their 1 location and $353.87 M in annual revenue in FY 2020. See insights on Corcept Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript Joseph Belanoff-- Chief Executive Officer. Andreas Grauer-- Chief Medical Officer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors Corcept Therapeutics Inc., down $1.02 to $21.96. The health care technology company said CEO Rusty Franz is stepping down, effective immediately. GameStop Corp., up $20.03 to $220.40

Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors. MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Corcept Therapeutics Incorporated (free visualization of insider trades). Of course, the past can be informative so you might be interested in considering this analytical visualization showing the company history of earnings and revenue

In connection with the settlement, Corcept has granted Sun the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for. MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors Corcept Therapeutics Incorporated has generated a total shareholder return of 18% over three years, so most shareholders would be reasonably content. But they probably don't want to see the CEO paid more than is normal for companies around the same size Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with. Corcept Therapeutics (CORT) Corcept Therapeutics. (CORT) $22.00. -0.24 (-1.08%) As of June 30 4:00:00 PM EST. License Error: Access from crawling bot. Q-Factor Score. The Q-Factor Score can be.

Joseph K. Belanoff, MD, CEO of Corcept Therapeutics, had the following to say about the news. We are gratified by the PTAB's decision. The '214 patent is directed to an important medical. Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders

Bob Roe - President - Corcept Therapeutics LinkedI

  1. istered with medications known as strong CYP3A inhibitors.
  2. Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and.
  3. Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript. 7 months ago - Seeking Alpha. Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View. Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year
  4. On June 15, 2021, Corcept Therapeutics Incorporated (Corcept) issued a press release announcing that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities (Sun) resolving patent litigation related to Korlym ®, Corcept's medication for the treatment of patients with Cushing's syndrome.The pending patent litigation was filed by Corcept.
  5. If you want to know who really controls Corcept Therapeutics Incorporated (NASDAQ:CORT), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger.
  6. I have been working at Corcept Therapeutics. Pros. The salaries are very competitive, even high compared to other pharmaceutical companies. CEO is warm, communicative and the employees like and respect him. Cons. There is a great deal of secrecy and lack of communication with employees from the president

Corcept Therapeutics Incorporated (CORT) CEO Joseph

MENLO PARK, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its 2017 financial results and provide a corporate update on Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call, by @nasda Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals? finance.yahoo.com - February 19 at 8:02 AM: Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript seekingalpha.com - February 10 at 5:47 PM: AMRX or CORT: Which Is the Better Value Stock Right Now About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's. Glassdoor gives you an inside look at what it's like to work at Corcept Therapeutics, including salaries, reviews, office photos, and more. This is the Corcept Therapeutics company profile. All content is posted anonymously by employees working at Corcept Therapeutics

About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Exploring Corcept Therapeutics (NASDAQ:CORT) stock? View CORT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe. Corcept Therapeutics shares last traded at $23.35, with a volume of 6,556 shares changing hands. Specifically, Director Daniel N. Swisher, Jr. sold 7,500 shares of the firm's stock in a transaction on Monday, April 5th. The stock was sold at an average price of $24.14, for a total value of $181,050.00. Following the completion of the sale, the.

Corcept Therapeutics - Wikipedi

  1. The other day, the Southern Investigative Reporting Foundation (SIRF) published a report on Corcept Therapeutics (CORT). Corcept Therapeutics is a small pharmaceutical company that markets Korlym (mifepristone) in a rare disease called Cushing's Syndrome, a condition that results from excessive exposure to the cortisol
  2. Corcept Therapeutics (NASDAQ:CORT) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports. The brokerage currently has a $24.00 price target on the biotechnology company's stock. Zacks Investment Research's price target would indicate a potential upside of 8.25% from the stock's previous close
  3. Joe Belanoff. Chief Executive Officer at Corcept Therapeutics. Chief Executive Officer at Corcept Therapeutics. Columbia University Vagelos College of Physicians and Surgeons. View profile badges

What Can We Make Of Corcept Therapeutics' (NASDAQ:CORT

  1. Belanoff is a co-founder of Corcept Therapeutics and has served as a member of our Board and as our Chief Executive Officer since 1999. In 2013 he was also appointed President. Dr. Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992
  2. Corcept Therapeutics CEO Joseph Belanoff's 2020 pay rises 16% to $5.8M. April 22, 2021. Corcept Therapeutics CEO Joseph Belanoff's 2019 pay falls 21% to $5M. April 27, 2020. Corcept Therapeutics CEO Joseph Belanoff's 2018 pay jumps 48% to $6.3M. April 24, 2019. About Corcept Therapeutics. Industry classifications
  3. CEO: Belanoff, Joseph K. Market: NASDAQ. Futu Hot List. HK US CN. Trade Heat Search Heat News Heat. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once.
SBBP Insider Trading Report - Strongbridge Biopharma plcMore Positive Data For Recordati Cushing's Drug :: Scrip

Corcept Therapeutics - Glucocorticoid Receptor Antagonist

  1. Joseph Belanoff is 62, he's been the President, Chief Executive Officer, and Director of Corcept Therapeutics Inc since 2014. There are 3 older and 7 younger executives at Corcept Therapeutics Inc. The oldest executive at Corcept Therapeutics Inc is George Baker, 77, who is the Independent Director
  2. MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Atabak Mokari has joined the company as Chief Financial Officer
  3. Corcept Therapeutics Sep 2010 - Nov 2013 3 years 3 months As company's first commercial employee and executive, launched company's first product after FDA approval
  4. Corcept Therapeutics CEO Joseph Belanoff's 2018 pay jumps 48% to $6.3M Corcept Therapeutics reports 2018 executive compensation. By ExecPay News. Published: April 24, 2019. Corcept Therapeutics reported fiscal year 2018 executive compensation information on April 24, 2019
  5. Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that former Gilead Sciences executive Gregg Alton has joined Corcept's Board of Directors
  6. MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors. Dr.
  7. Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to.

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3

Corcept Therapeutics Reviews Glassdoo

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic. Corcept Therapeutics Inc. Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe. View today's stock price, news and analysis for Corcept Therapeutics Inc. (CORT). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation.

The Insider Advantage

Corcept Therapeutics Appoints Kimberly Park to Board of

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Transcript May 7, 2021Seeking Alpha. Corcept suspends mid-stage NASH study after elevated liver. Approve of CEO. Joseph K. Belanoff. 6 Ratings Glassdoor gives you an inside look at what it's like to work at Corcept Therapeutics, including salaries, reviews, office photos, and more. This is the Corcept Therapeutics company profile. All content is posted anonymously by employees working at Corcept Therapeutics CORCEPT THERAPEUTICS INC sec form 4 filings insider trading, stock buying and selling

CEO.CA #cort Corcept Therapeutics Incorporated (CORT

MENLO PARK, CA--(Marketwired - June 22, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced today that Daniel N. Swisher, Jr. has been appointed to the company's Board of Directors in Menlo Park, CA. Doesn't Recommend. Approves of CEO. I have been working at Corcept Therapeutics. Pros. The salaries are very competitive, even high compared to other pharmaceutical companies. CEO is warm, communicative and the employees like and respect him. Cons. There is a great deal of secrecy and lack of communication with employees from.

Corcept Therapeutics' (CORT) CEO Joseph Belanoff On Q3

GlobeNewswire. Nov-18-20 05:40PM. U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcepts U.S. Patent No.10,195,214. GlobeNewswire. Nov-13-20 05:36AM. George Baker Is The Independent Director of Corcept Therapeutics Incorporated (NASDAQ:CORT) And Just Spent US$243k On Shares These new data underscore AT-527's potential to treat COVID-19 and to have an impact on global health, said Jean-Pierre Sommadossi, CEO of Atea. Earnings. Corcept Therapeutics announced preliminary fourth-quarter revenue of $85.7 million, lower than $87.9 million in the year-ago quarter, and GAAP EPS of 20 cents